Keros Therapeutics Inc (KROS)
45.64
-0.85
(-1.83%)
USD |
NASDAQ |
Jun 25, 16:00
45.64
0.00 (0.00%)
After-Hours: 20:00
Keros Therapeutics Cash from Operations (Quarterly): -44.56M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -44.56M |
| December 31, 2023 | -25.46M |
| September 30, 2023 | -33.98M |
| June 30, 2023 | -30.83M |
| March 31, 2023 | -34.24M |
| December 31, 2022 | -21.44M |
| September 30, 2022 | -24.60M |
| June 30, 2022 | -22.59M |
| March 31, 2022 | -1.427M |
| December 31, 2021 | -19.56M |
| September 30, 2021 | -14.44M |
| Date | Value |
|---|---|
| June 30, 2021 | -17.64M |
| March 31, 2021 | -10.50M |
| December 31, 2020 | -7.991M |
| September 30, 2020 | -10.86M |
| June 30, 2020 | -9.927M |
| March 31, 2020 | -8.12M |
| December 31, 2019 | -5.498M |
| September 30, 2019 | -2.955M |
| June 30, 2019 | -5.032M |
| March 31, 2019 | -2.513M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-44.56M
Minimum
Mar 2024
-1.427M
Maximum
Mar 2022
-17.58M
Average
-16.04M
Median
Cash from Operations (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | -81.52M |
| Biomarin Pharmaceutical Inc | 46.97M |
| Sarepta Therapeutics Inc | -242.08M |
| PTC Therapeutics Inc | 70.76M |
| ADMA Biologics Inc | -2.218M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.946M |
| Cash from Financing (Quarterly) | 156.80M |
| Free Cash Flow | -137.18M |
| Free Cash Flow Per Share (Quarterly) | -1.275 |
| Free Cash Flow to Equity (Quarterly) | -45.51M |
| Free Cash Flow Yield | -9.61% |